Holen Sie sich die Stockscreener-App
145.78
0.31%
0.159
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics (PTGX) CEO gifts stock to family - Stock Titan
Protagonist Therapeutics authorizes $300 million buyback plan - Investing.com
Protagonist Therapeutics Announces $300 Million Share Repurchase Program - ACCESS Newswire
Up to $300 million could go toward buying back shares at Protagonist Therapeutics. - Stock Titan
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight - GlobeNewswire Inc.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? - Yahoo Finance
Protagonist Therapeutics (PTGX) Stock Looks Fully Priced After Its 7x Run - simplywall.st
Research Analysts Offer Predictions for PTGX Q1 Earnings - marketbeat.com
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 - guardonline.com
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX) - The Globe and Mail
Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News - Yahoo Finance
Protagonist Therapeutics (NASDAQ:PTGX) Gets A Higher Price Target - Kalkine Media
BMO raises Protagonist Therapeutics price target on Mimrylo approval By Investing.com - Investing.com Canada
PTGX Maintained by BMO Capital -- Price Target Raised to $190 - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $190.00 Price Target at BMO Capital Markets - MarketBeat
The Bull Case For Protagonist Therapeutics (PTGX) Could Change Following FDA Approval Of MIMRYLO And Takeda Milestones - Yahoo Finance
Protagonist Therapeutics (PTGX) Could Be 63% Below Fair Value After Investor Update Call - Yahoo Finance
Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval? - Yahoo Finance
PTGX Maintained by Citigroup -- Price Target Raised to $182 - GuruFocus
Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says - marketscreener.com
Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept - marketscreener.com
Protagonist Therapeutics stock rating maintained at Buy by Clear Street - Investing.com
Jefferies reiterates Protagonist Therapeutics stock rating on Mimrylo label strength - Investing.com Canada
Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform By Investing.com - Investing.com Nigeria
Wolfe Research reiterates Protagonist Therapeutics stock rating at outperform - Investing.com
Protagonist to change PV narrative with Takeda Mimrylo win? - BioWorld News
PTGX Maintained by HC Wainwright & Co. -- Price Target Raised to $170 - GuruFocus
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia VeraSlideshow (NASDAQ:PTGX) 2026-08-31 - Seeking Alpha
132,351 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Legal & General Group Plc - MarketBeat
Protagonist Therapeutics Inc. (PTGX) Peer Comparison – Compare with Others - Value Research
Wellington Management Group LLP Sells 182,863 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Hsbc Holdings PLC Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - marketbeat.com
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Alyeska Investment Group L.P. - MarketBeat
58,059 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Twin Lakes Capital Management LLC - MarketBeat
The Manufacturers Life Insurance Company Purchases Shares of 108,555 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Acquires New Shares in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics receives FDA approval for polycythemia vera drug By Investing.com - Investing.com Canada
Bank of New York Mellon Corp Purchases New Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Bamco Inc. NY Makes New $1.96 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Elmind Capital LP Makes New $4.66 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Seven Fleet Capital Management LP Purchases 41,400 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
9,414 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by J. Goldman & Co LP - MarketBeat
Artia Global Partners LP Takes $2.81 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
ADAR1 Capital Management LLC Makes New $117.78 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Castleark Management LLC Buys Shares of 50,570 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Northwestern Mutual Wealth Management Co. Purchases New Shares in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Deutsche Bank AG Invests $17.39 Million in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
BlackRock Inc. Makes New Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
248,322 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Eagle Health Investments LP - MarketBeat
Great Lakes Advisors LLC Invests $6.97 Million in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178 - Moomoo
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 12-Month High on Analyst Upgrade - MarketBeat
PTGX Maintained by BMO Capital -- Price Target Raised to $178 - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, BMO Capital Markets Analyst Says - MarketBeat
Johnson & Johnson Invests $300.22 Billion in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity - ChartMill
Protagonist Therapeutics stock hits all-time high at 155.01 USD By Investing.com - Investing.com Australia
Protagonist Therapeutics stock hits all-time high at 155.01 USD - Investing.com
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):